Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 17/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000393 | 0.89 | AKT3 (0.77) | AKT3TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5006215 | 0.88 | AKT3 (0.79) | AKT3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5000573 | 0.80 | AKT3 (0.78) | AKT3 | |
| SCHEMBL5000295 | 0.79 | AKT3 (0.83) | AKT3 | |
| SCHEMBL5005814 | 0.78 | AKT3 (0.83) | AKT3 | |
| SCHEMBL4927968 | 0.78 | MAPT (0.54) | AKT3TAS1R3TAS1R1TAS1R2MAPT | |
| SCHEMBL5000614 | 0.77 | AKT3 (0.83) | AKT3 | |
| SCHEMBL5000382 | 0.77 | AKT3 (1.00) | AKT3NPC1POLB | |
| SCHEMBL5000539 | 0.76 | AKT3 (0.81) | AKT3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5000448 | 0.76 | AKT3 (1.00) | AKT3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |